Interesting but Par for the Course I was just re-reading the Immunocidin approval release of a couple of months ago. The one where they projected a very aggressive revenue figure of 1-2 mil annually. I believe that they had 72 reps at the time of this incredibly ballsy prognostication.
Since then, some of you may know, they have signed a distribution deal that adds 1,000 sales reps who will be eligeable to sell Immunocidin.
Considering the 14 fold increase in market coverage, has anyone seen a revised sales target or are they still running with the same 1-2 mil figure of the original 72 reps? I realize that this is a stretch but the current revenue projections call for $1,865.00 per rep, per annum on the top end. That is like asking the Toyota rep to sell 1 Camry per year...nearly impossible. Don't they know that there is still a recession!
When BNC goes to market with an slam dunk product they don't mess around!
Interesting but Par for the Course.